Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APECS II: Liposomal bupivacaine versus levobupivacaine PECS II block for mastectomy
NL-OMON59498Phase 3Not yet recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Oct 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial in postoperative pain and chronic pain comparing PECS II block with liposomal bupivacaine with PECS II block with levobupivacaine (2 arms). Primary endpoint: Postoperative NRS pain scores in the breast. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
liposomal bupivacainelevobupivacaine
03
Conditions
postoperative painchronic pain
Beyond the preview
Go deeper on NL-OMON59498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59498.